- Convenient total synthesis of taranabant (MK-0364), a novel cannabinoid-1 receptor inverse agonist as an anti-obesity agent
-
Being obese has various health problems that are related to type 2 diabetes mellitus, cardiovascular disease, hypertension, hyperlipidemia, and fibrinolytic abnormalities. Merck's taranabant (MK-0364), a CB1R inverse agonist, is currently in Phase 3 clini
- Kim, Min-ah,Kim, Jong Yup,Song, Kwang-Seop,Kim, Jeongmin,Lee, Jinhwa
-
p. 12845 - 12852
(2008/03/27)
-
- Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
-
Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo
- Chen, G-Yi,Frey, Lisa F.,Shultz, Scott,Wallace, Debra J.,Marcantonio, Karen,Payack, Joeseph F.,Vazquez, Enrique,Springfield, Shawn A.,Zhou, George,Liu, Ping,Kieczykowski, Gerard R.,Chen, Alex M.,Phenix, Brian D.,Singh, Utpal,Strine, Jeff,Izzo, Brianne,Krska, Shane W.
-
p. 616 - 623
(2012/12/31)
-